Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCamacho Soriano, Jessica
dc.contributor.authorRábano, Alberto
dc.contributor.authorMarazuela Fuentes, Paula
dc.contributor.authorBonaterra Pastra, Anna
dc.contributor.authorSerna Alonso, Garazi
dc.contributor.authorMoline Marimon, Teresa
dc.contributor.authorRamon y Cajal Agüeras, Santiago
dc.contributor.authorMartinez Saez, Elena Antima
dc.contributor.authorHernandez Guillamon, Maria Mar
dc.date.accessioned2022-05-02T12:49:06Z
dc.date.available2022-05-02T12:49:06Z
dc.date.copyright2021
dc.date.issued2022-01
dc.identifier.citationCamacho J, Rábano A, Marazuela P, Bonaterra-Pastra A, Serna G, Moliné T, et al. Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease. Brain Pathol. 2022 Jan;32(1):e13016.
dc.identifier.issn1750-3639
dc.identifier.urihttps://hdl.handle.net/11351/7435
dc.descriptionAlzheimer's disease; CD2AP; Pick's disease
dc.description.abstractGenome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesBrain Pathology;32(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAlzheimer, Malaltia d'
dc.subjectGenòmica
dc.subjectNeurones
dc.subject.meshAlzheimer Disease
dc.subject.meshNeurofibrillary Tangles
dc.subject.meshGenome-Wide Association Study
dc.titleAssociation of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1111/bpa.13016
dc.subject.decsenfermedad de Alzheimer
dc.subject.decsovillos neurofibrilares
dc.subject.decsestudio de asociación genómica completa
dc.relation.publishversionhttps://doi.org/10.1111/bpa.13016
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Camacho J, Ramón Y Cajal S, Martínez-Sáez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rábano A] Neuropathology Department, CIEN Foundation, Alzheimer’s Centre Queen Sofía Foundation, Madrid, Spain. [Marazuela P, Bonaterra-Pastra A, Hernández-Guillamon M] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Serna G] Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Moliné T] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34514662
dc.identifier.wos000695137100001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00275
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00465
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0019%2F0021
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CPII17%2F00010
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record